AMA Guides Digital Cedaron
Home
AMA Guides Editions ▾
  • 6th Edition 2025
  • 6th Edition 2024
  • 6th Edition 2023
  • 6th Edition 2022
  • 6th Edition 2021
  • 6th Edition 2008
  • 5th Edition
  • 4th Edition
  • 3rd Edition Revised
AMA Guides Newsletters Search Case Scenarios Subscribe Log In

AMA Guides® Newsletter - Issue Archive

Volume 24 (2019): Issue 2 (Mar) < Previous Issue Next Issue >

Articles

  1. Review of Symptoms and Signs for Working Adults with Median Nerve Entrapment

    J. Mark Melhorn, Kurt T. Hegmann

    Pages 3–5, 16

    DOI: 10.1001/amaguidesnewsletters.2019.MarApr01

    Abstract
    Physicians often must evaluate patients who present with symptoms in a median nerve distribution and typically diagnose carpal tunnel syndrome (CTS), but an accurate diagnosis is critical to determine causation and to define possible impairment. CTS is a constellation of symptoms and signs that result from mononeuropathy of the median nerve in the carpal tunnel; symptoms typically include tingling and/or numbness, dysesthesias, and/or pain in the radial palm and palmar aspect of the thumb, index, middle, and perhaps ring fingers. The American Academy of Orthopaedic Surgeons suggests use of the CTS-6 scoring aid (shown in a table) as a clinical aid for diagnosing CTS. Electrodiagnostic testing, nerve conduction studies in particular, are considered the gold standard for diagnosis of CTS, but research suggests that the definitions of relevant sensory and assignment of CTS are sensitive to threshold changes from a latency of, eg, >4.4 msec vs >4.5 msec. Other factors to consider include whether there are effects from the known association between wrist ratio and CTS and assessing the benefits of neuromuscular ultrasound to diagnose CTS. Nocturnal paresthesias and paresthesias while holding onto an object were sensitive indicators of the presence of CTS but use of the Phalen and Hoffmann-Tinel signs has significant potential to be unreliable.
  2. Amputation Evaluation: Sixth Edition Approaches

    Jay Blaisdell, James B. Talmage

    Pages 6–11

    DOI: 10.1001/amaguidesnewsletters.2019.MarApr02

    Abstract
    Upper extremity amputations are rated in the AMA Guides to the Evaluation of Permanent Impairment (AMA Guides), Sixth Edition, Section 15.6, Amputation Impairment, where text, tables, and figures guide evaluators in combining proximal diagnosis-based impairments (DBIs) and proximal range-of-motion impairments. The AMA Guides provides impairment grids for lower and upper extremity amputations, which are divided into five impairment classes (0 through 4), and each impairment class is further divided (except class 0) into five grades (A through E), each with its respective impairment rating that is expressed as a percentage of the extremity. Determining impairment class, and thus the default value of impairment, is straightforward if the amputation occurred directly at one of the points in the relevant grid; if the amputation occurred at another point, the evaluator should consult the appropriate figure to assess how the specific level of amputation corresponds with impairment percentages. An individual's proximal problems may lead to an increase in the impairment value because of the application of grade modifiers. Except in rare instances of bilateral upper extremity amputation or when the patient is unable to wear a prosthesis for a lower extremity amputation, the evaluator usually uses the default rating value within the selected impairment class as the final percentage rating. Evaluators are advised to re-read the amputation section in the AMA Guides before conducting an amputation evaluation.
  3. Impairment of Face-, Nose-, and Throat-related Structures Sixth Edition Approaches

    Jay Blaisdell, James B. Talmage

    Pages 12–14

    DOI: 10.1001/amaguidesnewsletters.2019.MarApr03

    Abstract
    Facial disfigurements, including those caused by burns (thermal, chemical, or electrical) or trauma, are rated in the AMA Guides to the Evaluation of Permanent Impairment (AMA Guides), Sixth Edition, Chapter 11, which also discusses occupational overexposure to sunlight, airborne chemicals, heavy metals, and allergens that may lead to head and neck cancers and degraded ability to breathe, chew, swallow, smell, or speak. Additional relevant impairments include those of olfaction and taste, chewing and swallowing, voice and speech, and of the upper respiratory passages. For upper air passage defects and voice and speech impairments, the evaluator assigns an impairment rating by selecting the relevant table or grid in Chapter 11 and then assigning the appropriate impairment class, as determined by the key factor. The patient's history is the key factor for upper air passage deficits, and the performance measures of audibility, intelligibility, and functional efficiency collectively act as the key factor for voice and speech impairments. Once they select an impairment class, evaluators can modify the rating within the impairment class by considering remaining variables. When rating the patient's ability to smell and taste or chew and swallow, raters do not use impairment classes or modifiers. Rather, they assign impairment within an allowable range largely based on professional judgment complemented by objective findings and a well-documented rationale.
  4. In the Literature: Disability Evaluation Abstracts

    Pages 15–15

    DOI: 10.1001/amaguidesnewsletters.2019.MarApr04

AMA Newsletter

Newsletter information

ISSN
2642-0880
Publisher
American Medical Association
Publication date
3/1/2019

© 2019 American Medical Association. All Rights Reserved.

AMA Guides Digital
Cedaron Medical

Products

  • AMA Guides® Digital Subscription
  • AMA Guides® Digital + Newsletter Archive
  • ImpairmentCare
  • Compare subscriptions

AMA Guides

  • Explore AMA Guides
  • AMA Guides Training Resources
  • Contact Us
  • Subscription Terms

Account

  • Overview
  • Organizations and seats
  • Orders

© 2026 Cedaron Medical Inc. All rights reserved.

AMA Guides® is a registered trademark of the American Medical Association. © 2026 American Medical Association. All Rights Reserved.

Privacy